Moteur de recherche d’entreprises européennes
Financement de l’UE (5 925 000 €) : Comorbidité et biologie de la synapse dans les troubles psychiatriques qui se chevauchent cliniquement Hor01/01/2016 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
Comorbidité et biologie de la synapse dans les troubles psychiatriques qui se chevauchent cliniquement
COSYN integrates outstanding European academic and three large Pharma to exploit genomic findings for intellectual disability (ID), autism, and schizophrenia. We capitalise on comorbidity, from clinic to cells and synapses, and have access to large existing samples. We focus on rare genetic variants of strong effect in patients with clinical comorbidity. Our aims are: (1) Understand comorbidity by comparing symptom and syndrome overlap with novel neurobiological criteria; (2) Elucidate mechanisms of comorbidity using neurobiology for the major genomic clue of synaptic dysfunction to unravel the cellular mechanisms of comorbidity; (3) Generate novel neuronal cell models by using advanced technologies to make neurons from carefully selected patients, and use genome editing to create or correct genetic variants. Multiple advanced neuroscience platforms are in place to evaluate an extensive set of molecular and cellular parameters, and to identify alterations in synaptic biology characteristic of ID, autism, and schizophrenia. These cellular models will, with Pharma partners, be up-scaled to provide “industry-standard” cellular assays for compound screening; (4) Refine diagnostic tools, use novel genomic and cellular features to improve disease classification and discriminate specific patient subtypes; and (5) Case studies in precision medicine: with Pharma partners, identify patients with a genetic change whose consequences can be reproducibly ameliorated in vitro by an approved medication. Recommend to the patient and clinician a double-blinded, N-of-one crossover case study to evaluate the clinical utility of a medication precisely indicated for that person. COSYN is an integrated, state-of-art, bench-to-bedside programme focused on personalised therapeutics. COSYN is a crucial next step in “decoding” the genetic findings via intensive focus on the clinical and molecular comorbidities of ID, autism, and schizophrenia.
| CEGAT GmbH | 100 000 € |
| Cardiff University | 225 000 € |
| F. HOFFMANN-LA ROCHE AG | 0,00 € |
| H. Lundbeck AS | 75 000 € |
| HELSINGIN YLIOPISTO | 225 000 € |
| Institut Pasteur | 225 000 € |
| Karolinska Institutet | 675 000 € |
| LIFE AND BRAIN GmbH | 300 000 € |
| MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN e. V. | 800 000 € |
| Region Hovedstaden | 75 000 € |
| Stichting VU | 1 925 000 € |
| 650 000 € | |
| 600 000 € | |
| 50 000 € |
https://cordis.europa.eu/project/id/667301
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.
Les visualisations de "CEGAT GmbH - Financement de l’UE (5 925 000 €) : Comorbidité et biologie de la synapse dans les troubles psychiatriques qui se chevauchent cliniquement"
sont mis à disposition par
North Data
et peuvent être réutilisées selon les termes de la licence
Creative Commons CC-BY.
